Pulmonary Arterial Hypertension (PAH) Market 2018: Insights, Epidemiology and Forecasts to 2027 - Trends and Opportunities - ResearchAndMarkets.com

DUBLIN--()--The "Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecasts to 2027" drug pipelines has been added to ResearchAndMarkets.com's offering.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Pulmonary Arterial Hypertension (PAH) from 2016 to 2027 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

This market report gives the thorough understanding of the Pulmonary Arterial Hypertension (PAH) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Pulmonary Arterial Hypertension (PAH) in the US, Europe, and Japan.

According to research, the global market of Pulmonary Arterial Hypertension (PAH) in 7MM was found to be USD 5.13 Billion in 2016.

The total number of prevalent population of Pulmonary Arterial Hypertension (PAH) was found to be more than 70,000 in 7MM, in the year 2016. Women account for 70% of the total prevalent cases.

Key Benefits:

  • This report will help to develop Business Strategies by understanding the trends shaping and driving the Pulmonary Arterial Hypertension (PAH) market
  • Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension (PAH) market
  • To understand the future market competition in the Pulmonary Arterial Hypertension (PAH) market

Companies Mentioned:

  • Actelion Pharmaceuticals Ltd.
  • Bayer AG
  • GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc.
  • Pfizer
  • United Therapeutics Corporation

Key Topics Covered:

1. Report Introduction

2. Pulmonary Arterial Hypertension Market Overview at a Glance

3. Pulmonary Arterial Hypertension (PAH): Overview

4. Epidemiology and Patient Population

5. Treatment Algorithm

6. Unmet Needs

7. Marketed Products

8. Emerging Therapies

9. Pulmonary Arterial Hypertension (PAH) Market Size

10. Market Drivers

11. Market Barriers

12. Report Methodology

13. Capabilities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/nj3x98/pulmonary?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs